- Home
- TMP vs STOK Comparison
TMP vs STOK Comparison
Compare TMP & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TMP
- STOK
- Stock Information
- Founded
- TMP 1836
- STOK 2014
- Country
- TMP United States
- STOK United States
- Employees
- TMP N/A
- STOK N/A
- Industry
- TMP Major Banks
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- TMP Finance
- STOK Health Care
- Exchange
- TMP Nasdaq
- STOK Nasdaq
- Market Cap
- TMP 892.4M
- STOK 721.4M
- IPO Year
- TMP N/A
- STOK 2019
- Fundamental
- Price
- TMP $71.19
- STOK $11.84
- Analyst Decision
- TMP Buy
- STOK Strong Buy
- Analyst Count
- TMP 1
- STOK 7
- Target Price
- TMP $68.00
- STOK $21.40
- AVG Volume (30 Days)
- TMP 50.7K
- STOK 562.4K
- Earning Date
- TMP 01-24-2025
- STOK 11-05-2024
- Dividend Yield
- TMP 3.38%
- STOK N/A
- EPS Growth
- TMP 376.41
- STOK N/A
- EPS
- TMP 4.64
- STOK N/A
- Revenue
- TMP $286,367,000.00
- STOK $16,742,999.00
- Revenue This Year
- TMP N/A
- STOK $103.04
- Revenue Next Year
- TMP $6.80
- STOK N/A
- P/E Ratio
- TMP $16.36
- STOK N/A
- Revenue Growth
- TMP 30.04
- STOK 81.08
- 52 Week Low
- TMP $43.09
- STOK $4.09
- 52 Week High
- TMP $79.01
- STOK $17.58
- Technical
- Relative Strength Index (RSI)
- TMP 46.17
- STOK 41.75
- Support Level
- TMP $73.07
- STOK $11.80
- Resistance Level
- TMP $78.47
- STOK $12.58
- Average True Range (ATR)
- TMP 1.99
- STOK 0.83
- MACD
- TMP -0.76
- STOK -0.06
- Stochastic Oscillator
- TMP 2.24
- STOK 8.32
About TMP Tompkins Financial Corporation
Tompkins Financial Corp is a Financial Holding Company. It has three business segments, consisting of banking, insurance and wealth management. It offers various products and services, including commercial and consumer banking, leasing, trust and investment management, financial planning and wealth management, and insurance. Insurance is comprised of property and casualty insurance services and employee benefit consulting. Wealth management activities include the results of the company's trust, financial planning, and wealth management services. The company generates majority of its revenue from Banking segment.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.